TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, cilt.25, sa.1, ss.58-67, 2022 (SCI-Expanded)
Introduction: Elderly patients with multiple myeloma have shorter survival outcomes than younger patients. In this study, we aimed to compare the efficacy and toxicity profiles of conventional and bortezomib-based therapy as first-line therapy in elderly patients with multiple myeloma and to determine the prognostic factors.